[Federal Register Volume 70, Number 75 (Wednesday, April 20, 2005)]
[Notices]
[Page 20600]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 05-7819]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importation of Controlled Substances; Notice of Application

    Pursuant to 21 U.S.C. 958(1)), the Attorney General shall, prior to 
issuing a registration under this Section to a bulk manufacturer of a 
controlled substance in Schedule I or II and prior to issuing a 
registration under 21 U.S.C. 952(a) (2) (b) authorizing the importation 
of such substances, provide manufacturers holding registrations for the 
bulk manufacture of the substance an opportunity for a hearing.
    Therefore, in accordance with 21 CFR 1301.34(a), this is notice 
that on August 13, 2004, Clinical Trial Services (US), Inc., 2661 
Audubon Road, Audubon, Pennsylvania 19403, made application by renewal 
to the Drug Enforcement Administration (DEA) for registration as an 
importer of Fentanyl (9801), a basic class of controlled substance 
listed in Schedule II.
    The company plans to import small quantities of the listed 
controlled substance in dosage form to conduct clinical trails.
    Any manufacturer who is presently, or is applying to be, registered 
with DEA to manufacture such basic classes of controlled substances may 
file written comments or objections to the issuance of the proposed 
registration and may, at the same time, file a written request for a 
hearing on such application pursuant to 21 CFR 1301.43 and in such form 
as prescribed by 21 CFR 1316.47.
    Any such written comments or objections being sent via regular mail 
may be addressed, in quintuplicate, to the Deputy Assistant 
Administrator, Office of Diversion Control, Drug Enforcement 
Administration, Washington, DC 20537, Attention: DEA Federal Register 
Representative, Liaison and Policy Section (ODL); or any being sent via 
express mail should be sent to DEA Headquarters, Attention: DEA Federal 
Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, 
Virginia 22301; and must be filed no later than May 20, 2005.
    This procedure is to be conducted simultaneously with and 
independent of the procedures described in 21 CFR 1301.34(b), (c), (d), 
(e), and (f). As noted in a previous notice published in the Federal 
Register on September 23, 1975, (40 FR 43745-46), all applicants for 
registration to import a basic class of any controlled substance listed 
in Schedule I or II are, and will continue to be required to 
demonstrate to the Deputy Assistant Administrator, Office of Diversion 
Control, Drug Enforcement Administration that the requirements for such 
registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 
1301.34(b), (c), (d), (e), and (f) are satisfied.

    Dated: April 11, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 05-7819 Filed 4-19-05; 8:45 am]
BILLING CODE 4410-09-P